[Treatment of osteoporosis with parathyroid hormone: evidence and perspective].
Parathyroid hormone (PTH) is a promising bone formation-stimulating agent, and the recent large-scale randomized controlled trial (RCT) revealed that parathyroid hormone increases and reduces lumbar bone mineral density and fracture risk, respectively, more potently than bisphosphonates. Moreover, PTH is also effective for male or glucocorticoid-induced osteoporosis. However, the recent studies showed that the co administration of PTH and bisphosphonate is not good. The further accumulation of evidence about the combined or subsequent therapy is expected.
Kaji
Hiroshi
H
Division of Endocrinology/metabolism, Neurology and Hematology/Oncology, Department of Clinical Molecular Medicine, Kobe University Graduate School of Medicine, Japan.
Sugimoto
Toshitsugu
T
D015519:Bone Density / Q000187:drug effects; D004164:Diphosphonates; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D015914:Estrogen Replacement Therapy; D019317:Evidence-Based Medicine; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects; D006801:Humans; D008297:Male; D010012:Osteogenesis / Q000187:drug effects; D010024:Osteoporosis / Q000139:chemically induced / Q000517:prevention & control*; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000517:prevention & control*; D010446:Peptide Fragments / Q000008:administration & dosage* / Q000494:pharmacology; D016032:Randomized Controlled Trials as Topic; D016103:Spinal Fractures / Q000209:etiology / Q000517:prevention & control; D013268:Stimulation, Chemical; D019379:Teriparatide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology
D004164:Diphosphonates; D005938:Glucocorticoids; D010446:Peptide Fragments; D019379:Teriparatide; C035748:parathyroid hormone (1-34)amide